You have been successfully subscribed!
From now on we will be bringing you all the latest news and developments in clinical diagnostics and scientific breakthroughs in the rare disease field - right to your inbox.
Find the shortest way back to our homepage
Physicians
Reveal the cause of genetic diseases
Support your patients with accurate information and helpful advice.
Patients
We guide you to the right desicions
Providing data and medical advise to support your most important questions.
Stay above the current with our latest scientific articles
-
Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia
The objective of this study is to define the clinical phenotype and natural history of sporadic adult-onset degenerative ataxia and to identify putative disease-causing mutations. The primary measure of disease severity was the Scale for the Assessment and Rating of Ataxia (SARA). DNA samples were screened for mutations using a high-coverage ataxia-specific gene panel in combination with next-generation sequencing. The analysis was performed on 249 participants. Our study provides quantitative data on the clinical phenotype and progression of sporadic ataxia with adult onset.
-
Heart and nervous system pathology in compound heterozygous Friedreich ataxia
In a small percentage of patients with Friedreich ataxia (FA), the pathogenic mutation is compound heterozygous, consisting of a guanine–adenine–adenine (GAA) trinucleotide repeat expansion in one allele, and a deletion, point mutation, or insertion in the other. In 2 cases of compound heterozygous FA, the GAA expansion was inherited from the mother, and deletions from the father.
-
Activation of PKC triggers rescue of NPC1 patient specific iPSC derived glial cells from gliosis
Niemann-Pick disease Type C1 (NPC1) is a rare progressive neurodegenerative disorder caused by mutations in the NPC1 gene. The pathological mechanisms, underlying NPC1 are not yet completely understood. Especially the contribution of glial cells and gliosis to the progression of NPC1, are controversially discussed. As an analysis of affected cells is unfeasible in NPC1-patients, we recently developed an in vitro model system, based on cells derived from NPC1-patient specific iPSCs.